---
{"dg-publish":true,"permalink":"/USMLE/Pharmacology/Phosphodiesterase inhibitors/","tags":["t2"]}
---

- Phosphodiesterase (PDE) inhibitors are a heterogenic class of drugs that target various isoforms of PDE enzymes. 
- <span style="background:rgba(240, 200, 0, 0.2)">Normally, the PDE decreases cAMP or [[USMLE/Biochemistry/Signal transduction\|cGMP]] in target cells by catalyzing the hydrolysis of these second messengers. </span>
- <span style="background:rgba(240, 200, 0, 0.2)">By inhibiting this step, PDE inhibitors actually increase cAMP and/or [[USMLE/Biochemistry/Signal transduction\|cGMP]] concentrations. </span>
- They are classified according to their target isoforms as nonspecific, PDE5, PDE4, and PDE3 inhibitors, each of which has a different clinical use.

| Feature                                | Nonspecific PDE Inhibitor           | PDE5 Inhibitor                                                       | PDE4 Inhibitor                                   | PDE3 Inhibitor                                                       |
|:-------------------------------------- |:----------------------------------- |:-------------------------------------------------------------------- |:------------------------------------------------ |:-------------------------------------------------------------------- |
| **Primary Second Messenger Increased** | cAMP & cGMP                         | **cGMP**                                                             | **cAMP**                                         | **cAMP**                                                             |
| **Primary Mechanism**                  | ↑cAMP & ↑cGMP -> Broad effects      | ↑cGMP -> Smooth muscle relaxation                                    | ↑cAMP -> ↓Inflammation, Bronchodilation          | ↑cAMP -> ↑Cardiac contractility, Vasodilation, ↓Platelet aggregation |
| **Key System/Tissue Focus**            | Broad (Airways, CNS)                | Vasculature (Penile, Pulmonary)                                      | Inflammatory Cells, Airways                      | Cardiovascular System, Platelets                                     |
| **Core Clinical Application(s)**       | Asthma/COPD (older)                 | Erectile Dysfunction, PAH                                            | COPD, Psoriasis/Psoriatic Arthritis              | Acute Heart Failure (IV), Claudication                               |
| **Defining Side Effect Concern(s)**    | Narrow Therapeutic Index (Toxicity) | Hypotension (esp. w/ Nitrates - **Contraindicated**), Visual changes | GI Upset (N/D), Weight Loss, Psychiatric Effects | **Arrhythmias**, Hypotension                                         |
| **Representative Drug**                | Theophylline                        | Sildenafil (Viagra)                                                  | Roflumilast (Daliresp), Apremilast (Otezla)      | Milrinone (Primacor), Cilostazol (Pletal)                            |
# Nonspecific phosphodiesterase inhibitors (inhibitors of PDE3, 4, and 5)
---
- Theophylline
## Indications
- [[USMLE/Respiratory/Chronic obstructive pulmonary disease\|COPD]] (severe and refractory cases)
- [[USMLE/Respiratory/Asthma\|Asthma]]
## Adverse effects
- General considerations
	- Close drug monitoring due to <span style="background:rgba(240, 200, 0, 0.2)">narrow therapeutic index (high risk of overdose).</span>
	- Metabolized in the liver by the <span style="background:rgba(240, 200, 0, 0.2)">[[USMLE/Pharmacology/Cytochrome P450\|cytochrome P450]] oxidase system.</span>
		- ↑ Risk of drug interactions (e.g., ciprofloxacin can increase theophylline serum levels).
- Cardiotoxicity
	- <span style="background:rgba(240, 200, 0, 0.2)">Tachycardia, arrhythmias</span>
- Neurotoxicity (dosage-dependent)
	- At low levels of overdose: dizziness, lightheadedness, headache
	- <span style="background:rgba(240, 200, 0, 0.2)">At high levels of overdose: seizures</span>
- Gastrointestinal (GI) toxicity
	- Severe refractory nausea and vomiting
	- [[USMLE/GI/Diarrhea\|Diarrhea]]
	- Abdominal pain
# Phosphodiesterase type 3 inhibitor (PDE3 inhibitor)
---
## Antiplatelets
- Agents
	- Cilostazol
	- Dipyridamole
- Indications
	- Intermittent vascular claudication
	- Antiplatelet (antianginal, TIA/stroke prevention)
	- Coronary stent restenosis prophylaxis
## [[USMLE/Cardiology/Heart failure\|Heart failure]] drugs
- Agent: <span style="background:rgba(240, 200, 0, 0.2)">Milrinone</span>
- Indications
	- Acute treatment of <span style="background:rgba(240, 200, 0, 0.2)">decompensated cardiac failure with cardiogenic shock</span>
- Mechanisms
	- Inhibition of smooth muscle proliferation
	- PDE3 inhibition → ↑ cAMP 
		- In the myocardium: ↑ cAMP → activation of calcium channels → <span style="background:rgba(240, 200, 0, 0.2)">cardiostimulatory effects → ↑ inotropy and ↑ chronotropy</span>
		- In peripheral vessels: ↑ cAMP → inhibition of myosin light chain kinase → smooth muscle relaxation → <span style="background:rgba(240, 200, 0, 0.2)">vasodilation with reduced cardiovascular preload and afterload</span>

# Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) 
---
>[!tip] 
>Vasodilators, see [[USMLE/Biochemistry/Signal transduction\|cGMP]] 
- <span style="background:rgba(240, 200, 0, 0.2)">Sildenafil</span>
- Tadalafil
- Avanafil
## Indications
- <span style="background:rgba(240, 200, 0, 0.2)">Erectile dysfunction</span>
- <span style="background:rgba(240, 200, 0, 0.2)">[[USMLE/Respiratory/Pulmonary hypertension\|Pulmonary hypertension]]</span>
- [[USMLE/Renal/Benign prostatic hyperplasia\|Benign prostatic hyperplasia]] (tadalafil only)
## Adverse effects
- Headache
- Lightheadedness
- Exanthema, flushing 
- <span style="background:rgba(240, 200, 0, 0.2)">Visual changes: photophobia, optic neuropathy, visual deficits (cyanopsia)</span>
	- Due to concomitant PDE 6 (photoreceptor) inhibition by PDE5 inhibitor in the retina.
- GI symptoms (e.g., dyspepsia)
- Runny nose, nasal congestion
